3,029 Bio-Rad Laboratories, Inc. $BIO Shares Sold by GW&K Investment Management LLC

GW&K Investment Management LLC reduced its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) by 1.8% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 163,876 shares of the medical research company’s stock after selling 3,029 shares during the period. GW&K Investment Management LLC owned 0.61% of Bio-Rad Laboratories worth $61,899,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the stock. Nisa Investment Advisors LLC increased its holdings in Bio-Rad Laboratories by 6.4% in the third quarter. Nisa Investment Advisors LLC now owns 648 shares of the medical research company’s stock valued at $245,000 after purchasing an additional 39 shares during the last quarter. Cetera Investment Advisers lifted its stake in Bio-Rad Laboratories by 0.6% in the first quarter. Cetera Investment Advisers now owns 7,596 shares of the medical research company’s stock valued at $2,117,000 after buying an additional 48 shares during the period. Rehmann Capital Advisory Group boosted its holdings in Bio-Rad Laboratories by 8.3% during the second quarter. Rehmann Capital Advisory Group now owns 954 shares of the medical research company’s stock worth $280,000 after buying an additional 73 shares during the last quarter. Hantz Financial Services Inc. boosted its holdings in Bio-Rad Laboratories by 7.6% during the third quarter. Hantz Financial Services Inc. now owns 1,142 shares of the medical research company’s stock worth $431,000 after buying an additional 81 shares during the last quarter. Finally, Oregon Public Employees Retirement Fund boosted its holdings in Bio-Rad Laboratories by 2.3% during the third quarter. Oregon Public Employees Retirement Fund now owns 3,808 shares of the medical research company’s stock worth $1,438,000 after buying an additional 86 shares during the last quarter. 65.24% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Bio-Rad Laboratories news, COO Jonathan P. Divincenzo sold 919 shares of the firm’s stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $390.47, for a total transaction of $358,841.93. Following the sale, the chief operating officer directly owned 1,962 shares in the company, valued at approximately $766,102.14. This trade represents a 31.90% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Courtney C. Enloe sold 902 shares of Bio-Rad Laboratories stock in a transaction that occurred on Tuesday, November 10th. The shares were sold at an average price of $386.17, for a total transaction of $348,325.34. Following the completion of the transaction, the executive vice president directly owned 750 shares in the company, valued at approximately $289,627.50. The trade was a 54.60% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 3,221 shares of company stock valued at $1,247,049. 30.34% of the stock is owned by corporate insiders.

Bio-Rad Laboratories Stock Down 0.8%

Shares of Bio-Rad Laboratories stock opened at $367.37 on Friday. Bio-Rad Laboratories, Inc. has a 1 year low of $236.73 and a 1 year high of $396.23. The business has a 50-day moving average of $371.86 and a two-hundred day moving average of $318.81. The company has a market capitalization of $9.88 billion, a P/E ratio of 9.68 and a beta of 1.06. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.18 and a quick ratio of 2.37.

Bio-Rad Laboratories (NYSE:BIO – Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The medical research company reported $2.65 EPS for the quarter, topping analysts’ consensus estimates of $2.23 by $0.42. Bio-Rad Laboratories had a return on equity of 3.58% and a net margin of 39.45%. The company had revenue of $656.40 million for the quarter, compared to analyst estimates of $649.94 million. During the same quarter last year, the firm posted $2.26 earnings per share. Bio-Rad Laboratories’s revenue was up .5% compared to the same quarter last year. As a group, equities analysts predict that Bio-Rad Laboratories, Inc. will post 9.71 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Citigroup boosted their target price on Bio-Rad Laboratories from $300.00 to $330.00 and gave the stock a “hold” rating in a research report on Wednesday, August 5th. Royal Bank Of Canada increased their price target on shares of Bio-Rad Laboratories from $390.00 to $440.00 and gave the company an “outperform” rating in a research report on Thursday, November 5th. Wells Fargo & Company lifted their price objective on shares of Bio-Rad Laboratories from $310.00 to $330.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 5th. Weiss Ratings raised shares of Bio-Rad Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research note on Monday, November 9th. Finally, Zacks Research upgraded shares of Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 11th. One investment analyst has rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $366.67.

View Our Latest Analysis on BIO

Bio-Rad Laboratories Profile

(Free Report)

Bio-Rad Laboratories, Inc. develops, manufactures, and markets products used in life science research and clinical diagnostics. Founded in 1952 by David and Alice Schwartz, the company is headquartered in Hercules, California, and serves customers around the world. Through its Life Science segment, Bio-Rad supplies instruments, reagents, and software for areas including cell biology, genomics, protein analysis, and drug discovery. Its products support research at academic institutions, biotechnology and pharmaceutical companies, and other laboratories.

Further Reading

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.